Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last 101.00 GBp
Change Today 0.00 / 0.00%
Volume 32.7K
AGL On Other Exchanges
As of 11:30 AM 05/22/15 All times are local (Market data is delayed by at least 15 minutes).

angle plc (AGL) Snapshot

101.00 GBp
Previous Close
101.00 GBp
Day High
101.00 GBp
Day Low
101.00 GBp
52 Week High
05/12/15 - 107.50 GBp
52 Week Low
01/26/15 - 53.75 GBp
Market Cap
Average Volume 10 Days
-0.05 GBp
Shares Outstanding
Dividend Yield
Current Stock Chart for ANGLE PLC (AGL)

Related News

No related news articles were found.

angle plc (AGL) Related Businessweek News

No Related Businessweek News Found

angle plc (AGL) Details

ANGLE plc, a medical diagnostic company, provides cancer diagnostics and foetal health products, and management services primarily in the United Kingdom. The company’s lead product includes Parsortix cell separation device, which captures very rare circulating tumor cells in cancer patient blood. The resulting liquid biopsy (simple blood test) enables the investigation of mutations in the patient’s cancer for personalized cancer care. ANGLE plc was founded in 2004 and is based in Guildford, the United Kingdom.

28 Employees
Last Reported Date: 07/22/14
Founded in 2004

angle plc (AGL) Top Compensated Officers

Founder, Group Chief Executive and Director
Total Annual Compensation: 458.0K GBP
Finance Director, Company Secretary and Direc...
Total Annual Compensation: 153.0K GBP
Compensation as of Fiscal Year 2014.

angle plc (AGL) Key Developments

ANGLE Plc Announces Ovarian Cancer Update

ANGLE plc announced that the Medical University of Vienna, one of its key opinion leaders, has published highly encouraging results in support of the use of the company’s Parsortix system in the detection of ovarian cancer. The study evaluated a total of 65 patients, comprising 42 cancer patients and 23 healthy normal volunteers. The cancer patients consisted of 24 ovarian cancer, 6 cervical cancer, 5 endometrial cancer and 7 breast cancer cases. The analysis of 7 RNA markers yielded 100% specificity, which indicates no false positives, a major problem with existing techniques.  The sensitivity of ovarian cancer was 80% at the point of diagnosis and 78% at relapse, which compares favourably to the 24.5% sensitivity, which is the best that has been achieved with other circulating tumour cell systems. The important new data shows that a sensitivity of 71% was achieved with the metastatic breast cancer patients, which is more than twice as high as achieved in studies using other CTC systems.  To improve the sensitivity further, the Medical University of Vienna reanalysed the RNA information using 30 RNA markers with the thresholds set for 100% specificity.  So far this work has been completed for 13 of the cancer patients.  The addition of 23 further RNA markers yielded an increased sensitivity level averaging 92% across all the cancer types.  Notably the sensitivity and specificity for the 7 ovarian cancer patients that were re-analysed were both 100% at diagnosis and at relapse.  This meant that all the ovarian cancer patients were correctly identified using the Parsortix blood test and there were no false positives or false negatives. Larger sample sizes will be needed to complete optimisation and confirm these improved results. With this new highly sensitive approach, the Medical University of Vienna undertook analysis of a woman at high risk of developing ovarian and breast cancer as a result of BRCA1/2 mutation.  The woman appeared healthy, had no symptoms and conventional diagnosis including ultrasound and the CA-125 serum tumour marker indicated that she was disease-free. However, like Angelina Jolie, the woman elected to undergo risk-reducing surgery to remove her ovaries. The Parsortix blood sample taken prior to surgery indicated that the woman was positive for ovarian cancer. This was initially thought to be a false positive. However, contrary to all the medical expectations and results from conventional diagnosis, when the surgery was undertaken the woman was in fact found to have ovarian cancer. This is only one case but it demonstrates the exceptional sensitivity of the Parsortix system and may provide a monitoring option for the approximately 1 in 380 women worldwide who are BRCA1/2 positive and at high risk of developing cancer. The Medical University of Vienna is now progressing a multi-centre prospective clinical study in ovarian cancer, which is expected to take around 18 months to complete.  The company is supporting this effort as a top priority. The company’s Parsortix system together with the RNA marker panel has the potential to help inform clinical decision-making for ovarian cancer patients in: Detection of cancer in high risk or genetically pre-disposed patients (detection); Monitoring therapy and selection of therapies in treatment of ovarian cancer patients (therapy monitoring); Monitoring of ovarian cancer patients in remission for early detection of relapse (remission monitoring). The company estimates that the ovarian cancer sales potential for the Parsortix system in Europe and the United States would be in excess of £300 million per annum.

EKF Molecular Diagnostics Collaborates with ANGLE

EKF Molecular Diagnostics has agreed a collaboration with ANGLE, to investigate the combination of ANGLE's Parsortix circulating tumour cell (CTC) harvesting platform with EKF Molecular's PointMan DNA enrichment technology as a liquid biopsy. If successful, the resulting simple blood test could enable the investigation of unexpected ultra-low level mutations in a patient's cancer for personalised cancer care. The collaboration will initially work on colorectal cancer and then expand to cover other cancer types. CTCs will be harvested from cancer patients' blood using ANGLE's Parsortix system and then analysed using PointMan DNA enrichment technology to identify genetic variation in the cancer. Both EKF Molecular Diagnostics and ANGLE believe that the combination of the Parsortix system with PointMan technology may be advantageous for two reasons. Firstly, the PointMan system preferentially amplifies variant sequences of interest whilst suppressing amplification of the wild type i.e. normal DNA. As a result, it has the potential to identify all mutations in gene sequences associated with clinical utility of targeted cancer therapies. In contrast, competing genetic analysis systems generally amplify only those areas which may be predicted to be mutant and therefore may miss unexpected mutations. Secondly, PointMan is highly sensitive with the ability to work with very low levels of target material, potentially as low as one CTC. The high purity of the Parsortix harvest (low white blood cell contamination) and its epitope independence may enable the combined system to be widely deployed across different cancer types and stages of disease. If the collaboration is successful, EKF Molecular Diagnostics and ANGLE will explore ways to offer their respective systems as a combined solution addressing first the pharma drug trial and research use market and then, as patient data are developed, the clinical market.

Angle Plc Announces Unaudited Consolidated Earnings Results for the Six Months Ended October 31, 2014

ANGLE Plc announced unaudited consolidated earnings results for the six months ended October 31, 2014. For the period, the company reported revenue of £288,000 against £414,000 a year ago. Operating loss was £1,613,000 against £556,000 a year ago. Loss before tax was £1,606,000 against £476,000 a year ago. Loss for the period attributable to owners of the parent company was £1,476,000 against £396,000 a year ago. Basic and diluted loss per share was £3.56 against £1.05 a year ago. Net cash used in operating activities was £1,445,000 against £747,000 a year ago. Purchase of property, plant and equipment was £153,000 against £84,000 a year ago. Purchase of intangible assets was £42,000 against £235,000 a year ago.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
AGL:LN 101.00 GBp 0.00

AGL Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for AGL.
View Industry Companies

Industry Analysis


Industry Average

Valuation AGL Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 27.2x
Price/Book 9.7x
Price/Cash Flow NM Not Meaningful
TEV/Sales 35.5x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ANGLE PLC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at